Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.
ACS Nano. 2022 Jun 28;16(6):8954-8966. doi: 10.1021/acsnano.1c11575. Epub 2022 May 31.
Viruslike particles (VLPs) fabricated using wireframe DNA origami are emerging as promising vaccine and gene therapeutic delivery platforms due to their programmable nature that offers independent control over their size and shape, as well as their site-specific functionalization. As materials that biodegrade in the presence of endonucleases, specifically DNase I and II, their utility for the targeting of cells, tissues, and organs depends on their stability in vivo. Here, we explore minor groove binders (MGBs) as specific endonuclease inhibitors to control the degradation half-life of wireframe DNA origami. Bare, unprotected DNA-VLPs composed of two-helix edges were found to be stable in fetal bovine serum under typical cell culture conditions and in human serum for 24 h but degraded within 3 h in mouse serum, suggesting species-specific endonuclease activity. Inhibiting endonucleases by incubating DNA-VLPs with diamidine-class MGBs increased their half-lives in mouse serum by more than 12 h, corroborated by protection against isolated DNase I and II. Our stabilization strategy was compatible with the functionalization of DNA-VLPs with HIV antigens, did not interfere with B-cell signaling activity of DNA-VLPs in vitro, and was nontoxic to B-cell lines. It was further found to be compatible with multiple wireframe DNA origami geometries and edge architectures. MGB protection is complementary to existing methods such as PEGylation and chemical cross-linking, offering a facile protocol to control DNase-mediated degradation rates for in vitro and possibly in vivo therapeutic and vaccine applications.
基于框架 DNA 折纸术制造的病毒样颗粒(VLPs)由于其可编程性,可独立控制其大小和形状,以及其特异性功能化,因此作为疫苗和基因治疗的递药平台而崭露头角。作为在存在内切核酸酶(特别是 DNase I 和 II)时可生物降解的材料,其靶向细胞、组织和器官的用途取决于其在体内的稳定性。在这里,我们探索了小沟结合物(MGBs)作为特定的内切核酸酶抑制剂,以控制框架 DNA 折纸术的降解半衰期。我们发现,由双螺旋边缘组成的裸、无保护的 DNA-VLPs 在典型的细胞培养条件下的胎牛血清中以及在人血清中 24 h 是稳定的,但在鼠血清中在 3 h 内降解,表明存在种属特异性的内切核酸酶活性。通过用二脒类 MGB 孵育 DNA-VLPs 来抑制内切核酸酶,可使它们在鼠血清中的半衰期延长超过 12 h,这与对分离的 DNase I 和 II 的保护作用相符。我们的稳定化策略与 DNA-VLPs 与 HIV 抗原的功能化兼容,在体外不干扰 DNA-VLPs 的 B 细胞信号转导活性,并且对 B 细胞系无毒。进一步发现它与多种框架 DNA 折纸术的几何形状和边缘结构兼容。MGB 保护与聚乙二醇化和化学交联等现有方法互补,为控制体外治疗和疫苗应用中 DNase 介导的降解速率提供了一种简便的方案。